First-choice drugs and combined protocols | LeishVet classification | ||
---|---|---|---|
Stage IIb (n = 14) | Stage III (n = 54) | Stage IV (n = 76) | |
a. First-choice drugsa | |||
ACEI | 14 (100%) | 46 (85.2%) | 60 (78.9%) |
ARB | 0% | 5 (9.3%) | 10 (13.2%) |
CCB | 0% | 2 (3.7%) | 4 (5.3%) |
Antithrombotic therapy | 0% | 1 (1.9%) | 2 (2.6%) |
b. Single-drug and combined protocolsb | |||
ACEI | 9 (64.3%) | 22 (40.7%) | 35 (46.1%) |
ACEI + NA | 4 (28.7%) | 7 (13.0%) | 0% |
ACEI + aldosterone receptor blockers | 0% | 1 (1.9%) | 1 (1.3%) |
ACEI + antithrombotic therapy | 0% | 6 (11.1%) | 11 (14.5%) |
ACEI + ARB | 1 (7.1%) | 4 (7.4%) | 9 (11.8%) |
ACEI + CCB | 0% | 2 (3.7%) | 3 (3.9%) |
ACEI + ARB + antithrombotic therapy | 0% | 0% | 3 (3.9%) |
ACEI + CCB + aldosterone receptor blockers | 0% | 0% | 1 (1.3%) |
ACEI + other | 0% | 5 (9.3%) | 2 (2.6%) |
SUM (ACEI with other compounds) | 1 (7.1%) | 18 (33.3%) | 30 (39.5%) |
ARB | 0% | 4 (7.4%) | 6 (7.9%) |
ARB + antithrombotic therapy | 0% | 1 (1.9%) | 1 (1.3%) |
CCB | 0% | 0% | 4 (5.3%) |
CCB + NA | 0% | 2 (3.7%) | 0% |
SUM (protocols without ACEI) | 0% | 7 (12.9%) | 11 (14.5%) |